Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
Kaposi sarcoma remains the most common malignancy among persons with HIV.
Lesions localized to the airway may cause bleeding, pain and dyspnea.
New therapeutic approaches for local disease are needed.
The purpose of this study is to compare the effectiveness of intralesional bevacizumab +
HAART vs HAART alone in treating localized Kaposi´s sarcoma of the airway in patients with
AIDS.
Phase:
Phase 2
Details
Lead Sponsor:
Centro de Investigación en. Enfermedades Infecciosas, Mexico